Investment Analysts’ updated eps estimates for Tuesday, March 31st:
Aclaris Therapeutics (NASDAQ:ACRS) had its outperform rating reiterated by analysts at Wedbush. They currently have a $8.00 target price on the stock.
accesso Technology Group (LON:ACSO) had its buy rating reaffirmed by analysts at Shore Capital Group Ltd.
Anixa Biosciences (NASDAQ:ANIX) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $10.00 price target on the stock.
Aprea Therapeutics (NASDAQ:APRE) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $7.00 target price on the stock.
ASML (NASDAQ:ASML) had its buy rating reissued by analysts at JPMorgan Chase & Co..
Actinium Pharmaceuticals (NYSE:ATNM) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $5.00 price target on the stock.
Anavex Life Sciences (NASDAQ:AVXL) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $24.00 target price on the stock.
Basf (OTCMKTS:BASFY) had its hold rating reaffirmed by analysts at Kepler Capital Markets.
Bicara Therapeutics (NASDAQ:BCAX) had its market outperform rating reiterated by analysts at Citizens Jmp. They currently have a $31.00 target price on the stock.
Bicara Therapeutics (NASDAQ:BCAX) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $30.00 price target on the stock.
Burlington Stores (NYSE:BURL) had its outperform rating reissued by analysts at Telsey Advisory Group. The firm currently has a $365.00 target price on the stock.
Calix (NYSE:CALX) had its buy rating reiterated by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $70.00 target price on the stock.
Colgate-Palmolive (NYSE:CL) had its hold rating reissued by analysts at TD Cowen. The firm currently has a $85.00 target price on the stock.
Centessa Pharmaceuticals (NASDAQ:CNTA) had its hold rating reiterated by analysts at Needham & Company LLC.
Centessa Pharmaceuticals (NASDAQ:CNTA) had its peer perform rating reissued by analysts at Wolfe Research.
Connect Biopharma (NASDAQ:CNTB) had its buy rating reiterated by analysts at BTIG Research. The firm currently has a $10.00 price target on the stock.
Costco Wholesale (NASDAQ:COST) had its outperform rating reaffirmed by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $1,125.00 price target on the stock.
CleanTech Lithium (LON:CTL) had its speculative buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a GBX 20 target price on the stock.
Debenhams Capital (LON:DEBS) had its hold rating reissued by analysts at Shore Capital Group Ltd.
DFS Furniture (LON:DFS) had its buy rating reaffirmed by analysts at Shore Capital Group Ltd.
Walt Disney (NYSE:DIS) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $125.00 price target on the stock.
EIKN (NASDAQ:EIKN) had its underperform rating reaffirmed by analysts at Wedbush. The firm currently has a $7.00 price target on the stock.
Equinix (NASDAQ:EQIX) had its buy rating reiterated by analysts at Truist Financial Corporation. They currently have a $1,127.00 price target on the stock, up from their previous price target of $1,087.00.
ESAB (NYSE:ESAB) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $130.00 target price on the stock, down from their previous target price of $150.00.
Vertical Aerospace (NYSE:EVTL) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $12.00 target price on the stock.
European Wealth Group (LON:EWG) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. The firm currently has a GBX 132 target price on the stock.
Flowserve (NYSE:FLS) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. They currently have a $90.00 price target on the stock, down from their previous price target of $100.00.
Fuller, Smith & Turner (LON:FSTA) had its buy rating reiterated by analysts at Shore Capital Group Ltd.
Greenland Technologies (NASDAQ:GTEC) was downgraded by analysts at Wall Street Zen from a buy rating to a hold rating.
Hayward (NYSE:HAYW) had its hold rating reissued by analysts at Jefferies Financial Group Inc.. The firm currently has a $15.00 price target on the stock, down from their previous price target of $16.00.
Humacyte (NASDAQ:HUMA) had its speculative buy rating reaffirmed by analysts at Benchmark Co..
IDEAYA Biosciences (NASDAQ:IDYA) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $52.00 target price on the stock.
InvenTrust Properties (NYSE:IVT) was downgraded by analysts at Wall Street Zen from a hold rating to a sell rating.
Judges Scientific (LON:JDG) had its buy rating reissued by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 5,600 price target on the stock.
J.Jill (NYSE:JILL) had its market perform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $16.00 target price on the stock.
Korea Electric Power (NYSE:KEP) was downgraded by analysts at Bank of America Corporation from a buy rating to a neutral rating.
Klarna Group (NYSE:KLAR) was downgraded by analysts at Wall Street Zen from a hold rating to a sell rating.
Knightscope (NASDAQ:KSCP) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $12.00 target price on the stock.
nLight (NASDAQ:LASR) was downgraded by analysts at Wall Street Zen from a buy rating to a hold rating.
Lincoln Electric (NASDAQ:LECO) had its hold rating reaffirmed by analysts at Jefferies Financial Group Inc.. They currently have a $280.00 price target on the stock, down from their previous price target of $350.00.
London Stock Exchange Group (LON:LSEG) had its buy rating reissued by analysts at Jefferies Financial Group Inc.. The firm currently has a £110 target price on the stock.
Middleby (NASDAQ:MIDD) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $195.00 target price on the stock.
Modine Manufacturing (NYSE:MOD) had its buy rating reiterated by analysts at DA Davidson. They currently have a $265.00 target price on the stock.
MSA Safety Incorporporated (NYSE:MSA) had its hold rating reissued by analysts at Jefferies Financial Group Inc.. The firm currently has a $180.00 target price on the stock, down from their previous target price of $200.00.
Niagen Bioscience (NASDAQ:NAGE) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They currently have a $13.00 target price on the stock.
Neumora Therapeutics (NASDAQ:NMRA) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $8.00 target price on the stock.
Neumora Therapeutics (NASDAQ:NMRA) had its buy rating reaffirmed by analysts at Guggenheim. The firm currently has a $14.00 price target on the stock.
Phreesia (NYSE:PHR) had its neutral rating reiterated by analysts at Robert W. Baird. The firm currently has a $10.00 target price on the stock, down from their previous target price of $25.00.
Phreesia (NYSE:PHR) had its hold rating reaffirmed by analysts at Truist Financial Corporation. Truist Financial Corporation currently has a $11.00 price target on the stock, down from their previous price target of $24.00.
Phreesia (NYSE:PHR) had its neutral rating reaffirmed by analysts at Citigroup Inc.. They currently have a $10.00 price target on the stock.
Phreesia (NYSE:PHR) had its neutral rating reissued by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $16.00 target price on the stock, down from their previous target price of $24.00.
Pentair (NYSE:PNR) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $125.00 price target on the stock, down from their previous price target of $135.00.
Plus Therapeutics (NASDAQ:PSTV) had its hold rating reiterated by analysts at D. Boral Capital.
Rockwell Automation (NYSE:ROK) had its hold rating reaffirmed by analysts at Jefferies Financial Group Inc.. They currently have a $380.00 target price on the stock, down from their previous target price of $490.00.
Sonic Automotive (NYSE:SAH) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $90.00 price target on the stock.
Spyre Therapeutics (NASDAQ:SYRE) had its buy rating reissued by analysts at BTIG Research. They currently have a $70.00 target price on the stock.
Tamboran Resources (NYSE:TBN) had its overweight rating reaffirmed by analysts at Piper Sandler. They currently have a $74.00 target price on the stock, up from their previous target price of $41.00.
TE Connectivity (NYSE:TEL) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. They currently have a $250.00 price target on the stock, down from their previous price target of $280.00.
Terns Pharmaceuticals (NASDAQ:TERN) had its hold rating reiterated by analysts at Truist Financial Corporation. The firm currently has a $53.00 target price on the stock, down from their previous target price of $56.00.
Tigo Energy (NASDAQ:TYGO) was downgraded by analysts at Wall Street Zen from a strong-buy rating to a buy rating.
Urogen Pharma (NASDAQ:URGN) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $33.00 price target on the stock.
Vertiv (NYSE:VRT) had its hold rating reissued by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $260.00 price target on the stock, down from their previous price target of $280.00.
Wabtec (NYSE:WAB) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. They currently have a $290.00 price target on the stock, down from their previous price target of $300.00.
Weyerhaeuser (NYSE:WY) had its buy rating reissued by analysts at DA Davidson. They currently have a $31.00 price target on the stock.
Xylem (NYSE:XYL) had its hold rating reissued by analysts at Jefferies Financial Group Inc.. The firm currently has a $130.00 target price on the stock, down from their previous target price of $140.00.
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
